





PHYSICIAN OFFICE CODING AND BILLING INFORMATION SHEET FOR NEULASTA® ONPRO®, NEULASTA®, AND NEUPOGEN®

Contact Amgen Assist 360™ for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.¹


Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.¹

Neulasta[®] Onpro[®] kit, which includes: the same Neulasta[®] as in the Prefilled Syringe with a different delivery option¹



- Must be prepared and applied by a healthcare provider on the same day as chemotherapy¹
- The prefilled syringe co-packaged in the Neulasta® Onpro® kit must only be used with the On-body Injector for Neulasta®
- Designed to deliver a full dose of Neulasta® approximately 27 hours after its activation¹
- As per the label, a healthcare provider may initiate administration with the On-body Injector for Neulasta® (also referred to as the "On-body Injector") on the same day as the administration of cytotoxic chemotherapy, and the On-body Injector is designed to deliver pegfilgrastim approximately 27 hours after application¹

Apply today, deliver* Neulasta® tomorrow¹



^{*} The On-body Injector for Neulasta® is designed to deliver Neulasta® approximately 27 hours after activation.

Important Safety Information

Contraindication

 Neulasta® or NEUPOGEN® are contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Please see additional Important Safety Information on pages 10-11.



Neulasta® delivered via the On-body Injector vs Neulasta® delivered via the manual use Neulasta® Prefilled Syringe

SELECT ATTRIBUTES	SAME	DIFFERENT
Active Ingredient ¹	✓	
Indication ¹	✓	
Route of Administration ¹	✓	
Deliverable Dose ¹	✓	
WAC ^{3,4}	✓	
J-code ^{5,} *	✓	
How Delivered and CPT Code ^{1,6,*}		✓
NDC Number ^{1,*}		/

^{*} See next page for coding and billing information sheet for Neulasta®. NDC = National Drug Code; WAC = wholesale acquisition cost.

On-body Injector for Neulasta®

A missed dose could occur due to an On-body Injector for Neulasta® failure or leakage. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use, as soon as possible after detection.

The On-body Injector is backed by 24/7 telephone support and a full return policy.

Call **1-844-MYNEULASTA** at any time for assistance or answers to product-related questions.

Important Safety Information

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Please see additional Important Safety Information on pages 10-11.



Physician Office – Billing Information Sheet for the Neulasta® Onpro® kit

Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Onpro® kit	J2506, injection, pegfilgrastim,	Neulasta® is supplied as a 6 mg deliverable dose.1
	excludes biosimilar, 0.5 mg	Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
		55513-0192-01 is the NDC number (in the 11-digit format) for Neulasta® Onpro® kit.¹
		Healthcare providers should ensure Service Units (Box 24G) are appropriately billed.
Administration of the On-body Injector	96377, application of on-body injector (includes cannula insertion) for timed subcutaneous injection	Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy. ^{1,*} See payer guidelines for specific coding requirements.
Office visit	Relevant Evaluation and Management (E&M) code ^{†,‡}	See payer guidelines.
Diagnosis/ Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}As long as Neulasta® is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen Assist 360™ for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1500 for Physician Office — Neulasta® Onpro® kit

Sample CMS 1500 Form — Physician Office Administration

MCDEADE MEDICAD MISSING CAST	PICA	NCE CLAIM FOR	JCC) 02/12				PICA
### STATE STATE ADDRESS NAME (aut home, First Name, Mode hinted)			_	- HEALTH PLAN - BLK LUNG -	R 1a. INSURED'S I.D. NUM	IBER (F	or Program in Item 1)
DOE, JOHN D XXX XXX F	J	. —	(IVIEITIDEI IL		4. INSUBED'S NAME (La	st Name. First Name. Midd	de Initial)
APPLIED I ADDRESS INC. Sweet Section APPLIED I RELATIONSHIP TO INSURING SECTION APPLIED I RELATIONSHIP TO INSURE SECTION APPLIED I RELATION APPLIED I RELATI	_					_	,
ANALYCOWN STATE A.RESENVED FOR NUCC USE CITY STATE				6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS	S (No., Street)	
PROCEDURE (XXX) XXXX - XXXXX PROCEDURE CODE (BOX 24D) PROCEDURE CODE		reet					
RESERVED FOR NUCC USE Note: Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy.* **As long as Neulasta* is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy.* **PATENT'S OR AUTHORIZED PERSON'S GIGNATURE: Insuring the relaxed in which information accesses the dain. I also request payment of government benefits either to myself or to the party who accepts assignment between 1.8 As a payment of delivered between 1.8 As a payment of providers of the party who accepts assignment benefits of the underliged physician or applier for providers the claim. I also request payment of government benefits either to myself or to the party who accepts assignment benefits of the underliged physician or applier for providers of the party who accepts assignment benefits of the underliged physician or applier for providers of the party who accepts assignment benefits of the underliged physician or applier for providers of the party who accepts assignment benefits of the underliged physician or applier for providers of the party who accepts assignment benefits of the underliged physician or applier for providers of the party who accepts assignment benefits of the underliged physician or applier for payment of providers of the party who accepts assignment benefits of the underliged physician or applier for payment of providers and party to provide a payment of providers of the party who accepts assignment benefits of the underliged physician or applier for payment of providers and party to provide a payment of providers and party to provide a payment of providers and payment of providers of the underliged physician or applier for payment of payment and payment of payments	Anytown	I	XX	8. RESERVED FOR NUCC USE			STATE
SUBCUTANEOUS Injection Note: Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy.* *As long as Neulasta* is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy. *PATENTS OR AUTHORIZED PRESONS SIGNATURE: Insurince the release of the information accessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment benefits to the underligened physician or supplier for services described below. **SIGNED** DATE** SIGNED** DATE** OUAL. DATE** SERVICE UNITS (BOX 246) Report units of service for Neulasta* OUAL. NOT DATE** OUAL.		1, ', '			ZIP CODE	/ IELEPHONE (In	dude Area Code)
Note: Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy.* *As long as Neulasta* is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy. **READ BACK OF FORM BEFORE COMPLETING **Assumed by the administration of cytotoxic chemotherapy.* *PATENT'S OR AUTHORIZED PRESDNS SIGNATURE! Lambrote ne relieus of hydroxic chemotherapy. **PATENT'S OR AUTHORIZED PRESDNS SIGNATURE! Lambrote ne relieus of hydroxic networks and the information necessary to process the dain. I also request payment of government benefits either to myself or to the party who accepts assignment benefits to the underlighed physician or applier for services described below. **SIGNED** **DATE** OUAL.* **DATE*		\ /		PROCEDURE CODE (BOY 24	D)		-
Note: Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy.* *As long as Neulasta* is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy. **READ BACK OF FORM BEFORE COMPLETING **Assumed by the administration of cytotoxic chemotherapy.* *PATENT'S OR AUTHORIZED PRESDNS SIGNATURE! Lambrote ne relieus of hydroxic chemotherapy. **PATENT'S OR AUTHORIZED PRESDNS SIGNATURE! Lambrote ne relieus of hydroxic networks and the information necessary to process the dain. I also request payment of government benefits either to myself or to the party who accepts assignment benefits to the underlighed physician or applier for services described below. **SIGNED** **DATE** OUAL.* **DATE*	OTTIET INCOMED O WANTE (E	ast Name, First Name, Wilder	initical)				
SUBCUTANEOUS Injection Note: Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy.* *As long as Neulasta* is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy. *PATENTS OR AUTHORIZED PRESONS SIGNATURE: Insurince the release of the information accessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment benefits to the underligened physician or supplier for services described below. **SIGNED** DATE** SIGNED** DATE** OUAL. DATE** SERVICE UNITS (BOX 246) Report units of service for Neulasta* OUAL. NOT DATE** OUAL.	OTHER INSURED'S POLICY	OR GROUP NUMBER		Use CPT® code representing prod	cedure performed,		
A Jong as Neulasta* is not delivered between 14 days before and 24 hours after administration of chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE Laumonce the release of any modale or other information necessary to be push who accepts assignment below. SIGNED DATE SIGNED ADDITIONAL CLAIMI DIAGNOSIS CODES (BOX 21) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. DIAGNOSIS CODE POINTER (BOX 24E) SPECIAL SERVICE BASE (From Box 2) - PROCEDURES SERVICES OR SUPPLIES M DO YV MM DD Y SERVICE IS (Company) and DATE	RESERVED FOR NUCC USE				njector (includes ca	nnula insertion) fo	
BEAD BLOC OF PORIS BEFORE COMPLETING & SUMMINISTRATION of Cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of Cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic chemotherapy. PATENTS OR AUTHORIZED PERSONS SIGNATURE: I administration of cytotoxic	RESERVED FOR NUCC USE						ody Injector on
PATENT'S OR JATHORIZED FERSIONS SIGNATURE to information necessary to proceed the date. I also request payment of government benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or to the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits either to myself or the party who accepts assignment benefits benefit to myself or the party who accepts assignment benefits benefit to myself or the party who accepts assignment benefits benefit to myself or the party who accepts assignment benefits benefit to myself or the party who accepts assignment benefits assignment benefits either to myself or the party who accepts assignment benefits assignment benefits either to myself or the party who accepts assignment benefits below. In A Country and the party of the party who accepts assignment benefits assignment benefits assignment benefits assignment benefits assignment and the moderation of supplier for services described below. In A Co				administration of cytotoxic cher		days before and 2	4 hours after
SIGNED DATE SIGNED DATE SIGNED DATE SIGNED DATE SIGNED ATTERNATION DATE SIGNED TO DATE SIGNED DATE SIGNED TO DATE SERVICE UNITS (BOX 24G) REPORT Units of service for Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). Noulasta® of accordance with the code descriptor (i.e., 12 service units = 6 mg). Noulasta® of accordance with the code descriptor (i.e., 12 service units = 6 mg). Noulasta® dose is 6 mg, per label. A DATE SERVICE SERVICE SERVICE SERVICE B. C. D. PROCEDURES SERVICES, OR SUPPLIES DATE SERVICE	PATIENT'S OR AUTHORIZE to process this claim. I also red	D PERSON'S SIGNATURE I a	uthorize the r	release of any medical or other information necessary	payment of medical b	enefits to the undersigned	
SERVICE DATE (BOX 24A) SOPTIAL CITY OF PREGNANCY (LMP) 15. OTHER DATE MM DD YY 16. DATES PATIENT UNABLE TO WORK IN CUPRENT OCCUPATION TO MM DD YY MM DD YY MM DD YY 16. HOSPITALIZATION DATES MM DD YY MM				DATE	OLONED.		
MM DD YY XX XX XX QUAL. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a. NAME OF REFUCE UNITS (BOX 24G) Report units of service for Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg). NAME OF REFUCE UNITS (BOX 24G) Report units of service or Neulasta® in accordance with the code descriptor (i.e., 12 service units = 6 mg)		SS. INJURY, or PREGNANCY	LMP) 15.0	OTHER DATE		ABLE TO WORK IN CURF	RENT OCCUPATION
ADDITIONAL CLAIM DIAGNOSIS CODES (BOX 21) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. DIAGNOSIS ODE POINTER (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE M DD YY MM DD YY SERVICE M DD YY M M DD YY SERVICE M DD YY M HATCH M THE COOL OF TO TWIN TO TWENT TO TWEN TO TWENT TO TWENT TO TWENT TO			' '	MM DD YY	FROM DD	TO MI	M DD YY
ADDITIONAL CLAIM DIAGNOSIS CODES (BOX 21) Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. ALLOWADIAGNOSIS CODE POINTER (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE M DO YY MM DO YY SERVICE M DO YY SERVICE MODIFER DIAGNOSIS CODE POINTER (BOX 24E) SPECIFY (Explain Junusual Circumstances) MODIFER DIAGNOSIS OF SERVICE (Explain Junusual Circumstances) MODIFER POUTER SCHARGES A XXX XX X	NAME OF REFERRING PRO	VIDER OR OTHER SOURCE	17a.		18. HOSPITALIZATION D		
Enter appropriate ICD-10-CM diagnosis code(s) corresponding to patient's diagnosis. Allowable diagnosis codes may vary by payer. DIAGNOSIS CODE POINTER (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE FIGHER TO	LOOP TO LOOP T				FROM i		
Eller alphophate Libration of the Code (s) Corresponding to patients diagnosis. Allowable diagnosis codes may vary by payer. DIAGNOSIS CODE POINTER (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE From To HALGEOF TO	DI,					Moulacta® i	
DIAGNOSIS CODE POINTER (BOX 24E) Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE From To PLACE OF TASSIGNMENT? SERVICE DATE (BOX 24A) Report date of service. For example, the date when On-body injector from the Neulasta® Onpro® kit was applied. FEDERAL TAX TO NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. Rsvd for NUCC Use SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (Lority) that the statements on the reverse of the reverse of the reverse of the reverse of the place of the p	DIA CNICCIO OD MATI				patient's diagnosis		
Specify diagnosis, from Box 21, relating to each CPT/HCPCS code listed in Box 24D. A. DATE(S) OF SERVICE From To PACE OF PACE	All All						
Specify diagnosis, from Box 21, relating to each CPT/HCPCs code listed in Box 24D. A. DATE(S) OF SERVICE From To PLACEOF M DD YY MM DD YY SERVICE EMG CPT/HCPCS MODIFIER M DD YY MM DD YY SERVICE EMG CPT/HCPCS MODIFIER X XX XX XX XX XX XX XX 11 J2506 A XXX XX XX XX XX I1 J-CODE (BOX 24D) J-CODE	UI/						dose is 6 mg,
M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (Explain Unusual Circumstances) M DD YY MM DD YY SERVICE EMG (CPT/HCPCS MODIFIER S CHARGES UNIT No.	Spe				listed in Box 24D.		
SERVICE DATE (BOX 24A) Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. - FEDERAL TAX ID: NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. Revd for NUCC Use 10. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()	From	To PLACE OF	(Expla	in Unusual Circumstances) DIAC NOSI	IS	G. H. I. DAYS EPSDT ID. OR Family QUAL.	J. RENDERING PROVIDER ID. #
SERVICE DATE (BOX 24A) Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. PEDEMAL TAX TO, NUMBER SIN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? POT 900. Claims, see balon Program 1. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse) 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH #	x xx xx xx	xx xx 11	J250	06 A	xxx xx	12 NPI	
SERVICE DATE (BOX 24A) Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. - FEDERAL TAX ID: NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. Revd for NUCC Use 10. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()	x xx xx xx	xx xx 11	9637				
SERVICE DATE (BOX 24A) Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. - FEDERAL TAX ID: NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? 28. TOTAL CHARGE 29. AMOUNT PAID 30. Revd for NUCC Use 10. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()		!	A				
Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. PEDEMAL TAX ID: NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? For good. claims, see back) YES NO \$ \$ 100. Revd for NUCC Use INCLUDING DEGREES OR GREDENTIALS. (Icertify that the statements on the reverse)	1 1		<u> </u>				
Report date of service. For example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. FEDERHAL TAX LD. NOMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? FOR 90% LORING. SEE BOOK SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? SSN EIN 26. PATIENT'S ACCOUNT NO. SSN EIN 27. ACCEPT ASSIGNMENT? SSN EIN 28. TOTAL CHARGE 29. AMOUNT PAID 30. Revd for NUCC Use NICLUDING DEGREES OR CREDENTIALS (ICCHITY HALE Statements on the reverse SSN EIN 20. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()				on a separate line with J	2506 and the JVV i	noamer.	
example, the date when On-body Injector from the Neulasta® Onpro® kit was applied. PELEHAL TAX ILL NUMBER SSN EIN 26. PATIENT'S ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (For good, daling, see back) \$ SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTALS (ILL NUMBER) 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH #	SERVICE DATE (BOX 24A)					
Unpro* kit was applied.				and the second s		NPI	
Unpro* kit was applied.	Report date of serv	vice. For					
SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (Lediffy that the statements on the reverse	Report date of servex	vice. For when On-body					
SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS 32. SERVICE FACILITY LOCATION INFORMATION 33. BILLING PROVIDER INFO & PH # ()	Report date of servexample, the date Injector from the N Onpro® kit was ap	vice. For when On-body Jeulasta® plied.					
	Report date of servexample, the date Injector from the N Onpro® kit was ap	vice. For when On-body Jeulasta® plied.	PATIENT'S A	(For govt. claims, see back)			
	Report date of sen example, the date Injector from the N Onpro® kit was ap FEDERAL TAX LD. NOMBER SIGNATURE OF PHYSICIAN INCLUDING DEGREES OR 8 (I certify that the statements or the statement	vice. For when On-body Jeulasta® plied. SSN EIN 26. F OR SUPPLIER REDEDNTIALS on the reverse		(For govt. claims, see back) YES NO	\$	29. AMOUNT PAID	



[†] Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

[‡] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when modifier 25 is billed.

Physician Office – Billing Information Sheet for the Neulasta® Prefilled Syringe

	, <u>, , , , , , , , , , , , , , , , , , </u>	
Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Prefilled	J2506, injection, pegfilgrastim,	Neulasta® is supplied as a 6 mg deliverable dose.1
Syringe for Manual Injection	excludes biosimilar, 0.5 mg	Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
		55513-0190-01 is the NDC number (in the 11-digit format) for the Neulasta® prefilled syringe for manual injection.1
		Healthcare providers should ensure Service Units (Box 24G) are appropriately billed.
Administration of Neulasta® Prefilled Syringe for Manual Injection	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Office visit	Relevant Evaluation and Management (E&M) code*,†	See payer guidelines.
Diagnosis/Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Important Safety Information

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta® and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1500 for Physician Office — Neulasta® Prefilled Syringe

Sample CMS 1500 Form — Physician Office Administration

回院 B 第2章 B 数 B			# #
HEALTH INSURANCE CLAIM FORM			CARRIER
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12		3	3
PICA		PICA TIT	<u> </u>
1. MEDICARE MEDICAID TRICARE CHAMPY	— HEALTH PLAN — BLK LUNG —	R 1a. INSURED'S I.D. NUMBER (For Program in Item 1)	1
(Medicare#) (Medicaid#) (ID#/DoD#) (Member II 2. PATIENT'S NAME (Last Name, First Name, Middle Initial)		4. INSURED'S NAME (Last Name, First Name, Middle Initial)	
Doe, John D	3. PATIENT'S BIRTH DATE SEX	Doe, John D	
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)	
5555 Any Street	Self Spouse Child Other		
Anytown XX	8. RESERVED FOR NUCC USE	CITY	<u>S</u>
ZIP CODE TELEPHONE (Include Area Code)		ZIP CODE TELEPHONE (Include Area Code)	Ž.
01010 (xxx) xxx-xxxx		()	5
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NUMBER	Ξ
a. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH SEX	AND INSURED INFORMATION
b. RESERVED FOR NUCC USE	b. AUTO ACCIDENT?	b. OTHER CLAIM ID (Designated by NUCC)	Ξ
	PLACE (State)	U. OTHER SEARN ID (Designated by NOCC)	A P
c. RESERVED FOR NUCC USE	c. OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR PROGRAM NAME	į
	PROCEDURE CODE (BOX 24D))	PATIENT
d. INSURANCE PLAN NAME OR PROGRAM NAME	Use CPT® code representing proce	edure performed, such as	ĭ
		or diagnostic injection (specify substance or drug);	
READ BACK OF FORM BEFORE COMPLETING 12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the to process this claim. I also request payment of government benefits either below.		or diagnostic injection (specify substance or drug),	
SIGNED	DATE	SIGNED	r
	OTHER DATE	16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION MM , DD , YY	
XX XX QUAL.	AL. MM DD YY	FROM i i TO i i	
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE 17a		18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES MM , DD , YY	
DIAGN	OSIS CODES (BOX 21)	ROM TO	
19. ADDITIC NAL CLAIM INFORMATION (Designated by NUC	propriate ICD-10-CM diagnosis	OUTSIDE LAB? \$ CHARGES	
	corresponding to patient's diagnosis	SERVICE UNITS (BOX 24G)	
Allowab	le diagnosis codes may vary by pay		
DIAGN	OSIS CODE POINTER (BOX 24E	accordance with the code descriptor	
F. L.	diagnosis, from Box 21, relating to	(i.e., 12 service units = 6 mg).	
24. A. DATE(S) OF SERVICE B. C. each CP	T/HCPCS code listed in Box 24D.	Neulasta® dose is 6 mg, per label.	z I
From To	CS MODIFIER POINTER	OR Family ID. RENDERLING S CHARGES UNITS Plan QUAL PROVIDER ID. #	∄
	■ V	, V	Ž
xx xx xx xx xx 11 J250	06 A	XXX XX 12 NPI	בָּ
0	70 1 5005 (000 040)		PPLIER INFORMATION
xx xx xx xx xx 11 963	, decoration,	<u></u>	4
3 1 1 1 1	J2506, injection, pegfilgrasti	m, excludes biosimilar, 0.5 mg.	<u> </u>
		d product should be reported	2
SERVICE DATE (BOX 24A)	on a separate line with J250	6 and the JW modifier. ⁷	5
			PHYSICIAN
date when Neulasta® prefilled syringe		NPI S	2
for manual injection was administered.			Ě
		NP1	1
25. FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S A	(For govt, claims, see back)	28. TOTAL CHARGE 29. AMOUNT PAID 30. Rsvd for NUCC Use	
31. SIGNATURE OF PHYSICIAN OR SUPPLIER 32. SERVICE FA	CILITY LOCATION INFORMATION	\$ \$	
INCLUDING DEGREES OR CREDENTIALS	CILITE LOCATION INFORMATION	33. BILLING PROVIDER INFO & PH # (
(I certify that the statements on the reverse apply to this bill and are made a part thereof.)			
SIGNED DATE a. NI	b.	a. D b.	
NUCC Instruction Manual available at: www.nucc.org	PLEASE PRINT OR TYPE	APPROVED OMB-0938-1197 FORM 1500 (02-12)	-
	. 22,.02 011 111 2		



[†] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when modifier 25 is billed.

Physician Office – Billing Information Sheet for NEUPOGEN®

NEUPOGEN® (filgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.8

Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
NEUPOGEN®	J1442, injection, filgrastim (G-CSF), 1 mcg	The NDC numbers for NEUPOGEN®, in the 11-digit format, are as follows:8 - 300-mcg vial: 55513-0530-10 - 300-mcg prefilled syringe: 55513-0924-10 - 480-mcg vial: 55513-0546-10 - 480-mcg prefilled syringe: 55513-0209-10
Administration	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Office visit	Relevant Evaluation and Management (E&M) code*,†	See payer guidelines
Diagnosis/ Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

Important Safety Information

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
- Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



The CMS 1500 for Physician Office — NEUPOGEN®

Sample CMS 1500 Form — Physician Office Administration

IEALTH INSURA	NCE CL	AIM FO	ORM									CARRIER
PPROVED BY NATIONAL UNI												Ī
PICA MEDICA	ID TRICA	ADE.	OLIAMBY	0.000	ID FEOA	OT IED	1a, INSURED'S I	D NUMBER		(F D-	PICA ogram in Item	<u> </u>
. MEDICARE MEDICA (Medicare#) (Medicaid			CHAMPV (Member II	O#) HEAL	JP TH PLAN FECA BLK LU (ID#)	ING OTHER	I Ia. INSURED S I	.D. NUMBER		(For Pro	ogram in i tem	" ↑
PATIENT'S NAME (Last Nam	ie, First Name, M	/liddle Initial)		3. PATIENT'S	BIRTH DATE	SEX	4. INSURED'S N	AME (Last Nam	ne, First Name,	Middle Ini	tia l)	
Doe, John I				XX X	X XX M	F		John				
PATIENT'S ADDRESS (No.,					RELATIONSHIP TO IN:	. —	7. INSURED'S A	DDRESS (No.,	Street)			
5555 Any St	rreer		STATE		Spouse Child	Other	CITY				STATE	',
Anytown			XX	6. NESERVE	D FOR NOCC USE		CITY				SIAIL	0
IP CODE	TELEPHONE	(Include Are	ea Code)				ZIP CODE		TELEPHON	E (Include	Area Code)	
01010	(xxx)	xxx-	xxxx						()		ÖB
OTHER INSURED'S NAME (Last Name, First	t Name, Middl	lle Initial)	10. IS PATIEN	IT'S CONDITION REL	ATED TO:	11. INSURED'S I	POLICY GROU	P OR FECA N	JMBER		Ĭ.
OTHER INSURED'S POLICY	OR GROUP NI	IMRER		a EMPLOVM	ENT? (Current or Prev	ious)	a. INSURED'S D	ATE OF DIDTU	1		SEX	
OTTENTINGOTED OT OLIOT	Orranoor No	JWIDETT		Га. Е.М. Е.О.Т.М	YES N		MM	DD YY	М		F 🗆	
RESERVED FOR NUCC USI	=			b. AUTO ACC	LIDENT2	PLACE (State)	b. OTHER CLAIM	I IID (Designate		Ш		PATIENT AND INSUBED INFORMATION
				[YES N							NA NA
DESERVED FOR NUCCIUSE				c. OTHER AC			c. INSURANCE F	PLAN NAME OF	R PROGRAM N	IAME		I L
J-CODE (BOX 24				40.1.61.111.1	YES N		4 IO TI :==== :::	OTHER	I DELIES -	ANIO		
J1442, injection, fi				10d. CLAIM C	ODES (Designated by	NUCC)	d. IS THERE AN	DTHER HEALT			0 0	٩
Note: If applicable				& SIGNING T	HIS FORM.		13. INSURED'S (<u> </u>	If yes, comple			-
should be reported J1442 and the JW		arate line			nedical or other informat he party who accepts as			edical benefits				
TI442 and the JVV	mounter.			,		ŭ.						
SIGNED					=	DIAGN	OSIS CODE	(BOX 21)			
. D TE O CURRENT ILLNE	SS INTITIES or	DDECNIANO										_
		FREGIVANO	Y (LMP) 15.0	OTHER DATE	MM DD	Docume	nt appropria			nosis	DCCUPATION DD YY	y †
XX XX CX	QUAL.		QUA	AL.	MM DD			te ICD-10	- -CM diagr			
XX XX CX	QUAL.		QUA	AL.	MM DD	code(s) c	nt appropria	te ICD-10- g to patie	-CM diagr nt's diagn	osis.	SERVICES	
XX: XX XX (QUAL. OVIDER OR OT	HER SOURC	QUA DE 17a 17b	AL.	MM DD	code(s) c	nt appropria correspondin	te ICD-10- g to patien codes may	-CM diagr nt's diagno v vary by p	osis.		
XX XX XX (N ME C F REFERRING PR	QUAL. OVIDER OR OT RMATION (Desig	HER SOURC	QUA DE 17a 17b	AL.		code(s) code(s	nt appropria correspondin le diagnosis	te ICD-10- g to patie codes may	-CM diagr nt's diagno vary by p	osis. Jayer.		
X3 X X XX C	QUAL. OVIDER OR OT RMATION (Desig	HER SOURC	QUA DE 17a 17b	AL.		code(s) code(s	nt appropria correspondin le diagnosis OSIS CODE	te ICD-10- g to patiel codes may (BOX 24 om Box 21	-CM diagr nt's diagno vary by p IE) , relating	osis. Jayer.		
X2 X XX C N ME C REFERRING PR	QUAL. OVIDER OR OT RMATION (Desig	HER SOURC	QUA DE 17a 17b	AL.		code(s) code(s	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS cod	te ICD-10- g to patiel codes may (BOX 24- om Box 21 de listed in	-CM diagr nt's diagn vary by p IE) , relating of Box 24D.	osis. Jayer.		
X2 X XX C N ME C REFERRING PR	QUAL. OVIDER OR OTI RMATION (Desig	HER SOURC	CC) 17a 17b CC) Late A-L to servi C. L G. L	AL.	24E) ICD Ind.	code(s) code(s	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro	te ICD-10- g to patiel codes may (BOX 24- om Box 21 de listed in	-CM diagr nt's diagn vary by p IE) , relating of Box 24D.	osis. Jayer.		
XX X XX C N MME OF REFERRING PR A DITTIC VAL CLAIM INFOF D AGNOSIS OR NATURE C XXX X L	OUAL. OVIDER OR OT MATION (Design FILLNESS OR B. L	HER SOURC	QU/ 17a 17b 17b CC)	NPI NPI Ce line below (2	24E) ICD Ind.	code(s) c Allowabl DIAGNO Specify c each CP	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo	te ICD-10- g to patier codes may ((BOX 24) om Box 21 de listed in	CM diagr nt's diagno vary by p IE) , relating of Box 24D.	osis. Payer. to	SERVICES DD YY	,
N ME OF REFERRING PR A DITIONAL CLAIM INFOF D AGNOSIS OR NATURE O XXX • X L D DATE(S) OF SERVI	DUAL. OVIDER OR OT MATION (Design FILLNESS OR B J CE	nated by NUC	CC) 17a 17b CC) Late A-L to servi C. L G. L K. L D. PROCE	DURES, SERV	24E) ICD Ind.	code(s) code(s	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo	te ICD-10- g to patier codes may ((BOX 24- om Box 21- de listed in	CM diagram's diagnam's diagnam's diagnam's vary by parties (1988), relating Box 24D. UMBER HOTEL ID. FROM ID.	osis. Payer. to	SERVICES DD YY	, N
N ME OF REFERRING PR A DITIC VAL CLAIM INFOF D AGNOSIS OR NATURE O XXX . X L D DATE(S) OF SERVI	DUAL. OVIDER OR OT	INJURY Rel	CC) Late A-L to servi C. L. G. L. K. L. D. PROCE C. D. BACE	DURES, SERV in Unusual Circ	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	Code(s) c Allowabl DIAGNO Specify c each CP DIAGNOSIS PO NTER	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coc 23. PRIOR AUTH	te ICD-10- g to patiet codes may (BOX 24 pm Box 21 de listed in HORIZATION N GRAYS OR UNITS	-CM diagram's diagram's diagram's diagram's vary by partial pa	osis. ayer. to RVICE	SERVICES DD YY	, Z (BOX 2
NAME OF REFERRING PR A DITIC VAL CLAIM INFOF D AGNOSIS OR NATURE OF XXX - X L D ATTE (S) OF SERVI	DUAL. OVIDER OR OT	INJURY Rel	CC) 17a 17b CC) Late A-L to servi C. L G. L K. L D. PROCE	DURES, SERV in Unusual Circ	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	code(s) c Allowabl DIAGNO Specify c each CP	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH S CHARGES	te ICD-10- g to patier codes may ((BOX 24) om Box 21 de listed in	-CM diagrint's diagnin's vary by parts of the parts of th	osis. ayer. to RVICE port ur	J. RENDERING UNITS (hit of servi	(BOX 2:
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT OTTO OTTO OTTO OTTO OTTO OTT	B. C.	CC) Iate A-L to servi C. L G. L K. L D. PROCE C. Da CPT/HCP	NPI NPI DURES, SERV In Unusual Circ	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	Allowabi	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint's vary by p IE) , relating: , relating: Box 24D. UMBER LID. FRINT SE FRINT	osis. to RVICE port ur J1442	SERVICES DD YYY RENDERING UNITS (ait of servicespool	(BOX 2) ice. 1 urands to
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT OTTO OTTO OTTO OTTO OTTO OTT	INJURY Rel	CC) Late A-L to servi C. L. G. L. K. L. D. PROCE C. D. BACE	NPI NPI DURES, SERV In Unusual Circ	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	Code(s) c Allowabl DIAGNO Specify c each CP DIAGNOSIS PO NTER	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet codes may (BOX 24 pm Box 21 de listed in HORIZATION N GRAYS OR UNITS	-CM diagrint's diagnin's vary by parts	cosis. to RVICE port ur J1442 ncg of	J. RENDERING UNITS (hit of servi	(BOX 2 ice. 1 ur ands to EN®; for
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT ILLNESS OR B. L. J. L. J. L. CE DD YY S	INJURY Rel	CC) Iate A-L to servi C. L G. L K. L D. PROCE 3 CPT/H P	AL NPI ce line below (2 DURES, SERV in Unusual Circoss 12	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	Allowabi	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2 ice. 1 urinds to EN®; for the 180 unit
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT ILLNESS OR B. L. J. L. J. L. CE DD YY S	INJURY Rel	CC) Iate A-L to servi C. L G. L K. L D. PROCE C. Da CPT/HCP	AL NPI ce line below (2 DURES, SERV in Unusual Circoss 12	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES sumstances)	Allowabi	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units	(BOX 2 ice. 1 urinds to EN®; for the 180 unit
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OTHER OR OTHER OR OTHER OR OTHER OR OTHER	INJURY Rel B. C. BEERWICE EMG 11	CODE (Butt admir	DURES, SERVIN IN UNIVERSITY ON 24D) OX 24D) instration visits and the service of the service o	24E) ICD Ind. D. H. L. ICES, OR SUPPLIES MODIFIER	Code(s) c Allowabl DIAGNO Specify c each CP DIAGNOSIS PONTER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2: ice. 1 ur onds to EN®; for s for the 880 unit ose.
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT IMATION (Design of ILLNESS OR B. L. J. J. L. J. J. L. J. L. J. L. J. J. L. J. J. L. J. L. J. J. L. J. J. J. L. J. J. J. L. J.	INJURY Rel INJURY	CCDE (Bduct admir r code. Us	DURES, SERV In Unusual Circos 22 OX 24D) instration vec CPT code	24E) ICD Ind. D. H. ICES, OR SUPPLIES unstances) MODIFIER	Code(s) c Allowabl DIAGNO Specify c each CP DIAC NOSIS PO VITER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2: ice. 1 ur onds to EN®; for s for the 880 unit ose.
X2 X X XX N ME C FREFERRING PR D AGNOSIS OR NATURE C XXX X D AGNOSIS OF SERVI D D YY MM XX XX XX XX	DUAL. OVIDER OR OT OT IMATION (Design of ILLNESS OR B. L. J. J. L. J. J. L. J. L. J. L. J. L. J. L. J. L. J. J. L. J. J. L. J. L. J. L. J. J. L. J. J. L. J. J. L. J. J. J. L. J.	INJURY Rel INJURY	CC) Iate A-L to servi C. L G. L K. L D. PROCE GODE (Boldert admir CODE (Boldert admir Code. Uspermed, suc	DURES, SERV In Unusual Circos 22 OX 24D) distration vec CPT code ch as 9637	D. L. L. L. L. L. MODIFIER With le representing 72, therapeutic	Code(s) c Allowabl DIAGNO Specify c each CP DIAC NOSIS PO VITER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2: ice. 1 ur onds to EN®; for s for the 880 unit ose.
X2 X X XX CO. NAME OF REFERRING PR DAGNOSIS OR NATURE OF XXX X A DATE(S) OF SERVI M DD YY MM CX XX XX	DUAL. OVIDER OR OT OT IMATION (Design of ILLNESS OR B. L. J. J. L. CE DD YY S XX X	INJURY Rel B. C. BERNICE EMC 11 11 cent produriate CPT ure perfolactic, or	CODE (Buct admir I code. Us or diagnosti	DURES, SERV in Unusual Circos 72 OX 24D) instration vector of the Service of t	D. L. L. L. LICES, OR SUPPLIES umstances) MODIFIER with le representing 72, therapeutic (specify	Code(s) c Allowabl DIAGNO Specify c each CP DIAGNOSIS PONTER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n conization n conization n	-CM diagrint's diagnint's diagnint	RVICE Doort ur J1442 ncg of ample, o mcg	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2dice. 1 urinds to EN®; for the 180 units ose.
XX XX XX C NAME OF REFERRING PR LA DITIC VAL CLAIM INFOF DAGNOSIS OR NATURE O XXX X A DATE(S) OF SERVI M DD YY MM CX XX XX XX CX XX XX XX CX XX XX	DUAL. OVIDER OR OT OTHER OR OTHER OR OTHER OR OTHER OR OTHER OR OTHER OR OTHER	B. C. SERVICE EMC 11 11 11 contact production of contact c	CODE (Buct admir I code. Us or diagnosti	DURES, SERV in Unusual Circos OX 24D) inistration we CPT code that as 9637 c injection utaneous cure.	D. L. L. L. L. L. MODIFIER With le representing 72, therapeutic	Code(s) c Allowabl DIAGNO Specify c each CP DIAC NOSIS PO NTER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH 5. 5. 5. 6. 7. 8. CHARGES	te ICD-10- g to patiet g to patiet codes may g (BOX 24 m Box 21 de listed in lorization n lorization n xxx xxx	-CM diagrint's diagnint's diagnint	RVICE RVICE Over ur J1442 ncg of mcg of the 48	J. RENDERING UNITS (it of servi correspo NEUPOG 300 units dose or 4	(BOX 2- ice. 1 urinds to EN®; fors for the 180 units
XX XX XX CO. NAME OF REFERRING PR A DOTTIC NAL CLAIM INFOF XXX X A DATE(S) OF SERVI M DD YY MM XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX	DUAL. OVIDER OR OT OT OTHER OR OT OTHER OR OT OTHER OR OTHER	B. C. BERNICE EMG 11 11 EDURE (elect production) and the production of the produc	CODE (B. duct admir F code. Us ormed, suc diagnostic ug); subcut.	DURES, SERV in Unusual Circles OX 24D) vistration vec CPT code has 9637 c injection circles in Company in Com	With le representing 72, therapeutic of specify or intramuscula	Code(s) c Allowabl DIAGNO Specify c each CP DIAC NOSIS PO NTER A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH S CHARGES XXX XXX 28. TOTAL CHAI \$	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n	-CM diagrint's diagnint's diagnint's diagnint's diagnint's vary by p. F. C.	RVICE RVICE Over ur J1442 ncg of mcg of the 48	RENDERING WINITS (a) it of servicorrespo NEUPOG 300 units dose or 4 30 mcg do	(BOX 2- ice. 1 urinds to EN®; fors for the 180 units
XX XX XX CO. NAME OF REFERRING PR A DOTTIC NAL CLAIM INFOF XXX X A DATE(S) OF SERVI M DD YY MM XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX XX	DUAL. OVIDER OR OT OT IMATION (Design of ILLNESS OR B. L. J.	INJURY Rel INJURY	CODE (B. duct admir F code. Us ormed, suc diagnostic ug); subcut.	DURES, SERV in Unusual Circles OX 24D) vistration vec CPT code has 9637 c injection circles in Company in Com	Vith le representing 72, therapeutic 1 (specify or intramuscula	A A A A A A A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH S CHARGES XXX XXX 28. TOTAL CHAR	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n	-CM diagrint's diagnint's diagnint's diagnint's diagnint's vary by p. F. C.	RVICE RVICE Over ur J1442 ncg of mcg of the 48	RENDERING WINITS (a) it of servicorrespo NEUPOG 300 units dose or 4 30 mcg do	(BOX 2- ice. 1 urinds to EN®; fors for the 180 units
XX XX XX A DOTTIC VAL CLAIM INFOF D AGNOSIS OR NATURE CO XXX X A DATE(S) OF SERVI M DD YY MM XX XX XX XX XX	DUAL. OVIDER OR OT OT IMATION (Design of ILLNESS OR B. L. J.	INJURY Rel INJURY	CC) Late A-L to service C. L. G. L. K. L. D. PROCE J144 9637 CODE (Bout admir code. Uspermed, such addirect admir code. Uspermed. Such admir code. Such ad	DURES, SERV in Unusual Circles OX 24D) vistration vec CPT code has 9637 c injection circles in Company in Com	With le representing 72, therapeutic of specify or intramuscula	A A A A A A A	nt appropria correspondin le diagnosis OSIS CODE diagnosis, fro T/HCPCS coo 23. PRIOR AUTH S CHARGES XXX XXX 28. TOTAL CHAI \$	te ICD-10- g to patiet g to patiet codes may g (BOX 24 pm Box 21 de listed in conization n	-CM diagrint's diagnint's diagnint's diagnint's diagnint's vary by p. F. C.	RVICE RVICE Over ur J1442 ncg of mcg of the 48	RENDERING WINITS (a) it of servicorrespo NEUPOG 300 units dose or 4 30 mcg do	(BOX 2 ice. 1 urinds to EN®; for the 180 unit ose.



[†] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when Modifier 25 is billed.

Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient's skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient's skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient. Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852).

Indication and Important Safety Information for Neulasta® (pegfilgrastim) and NEUPOGEN® (filgrastim)

Indication

Neulasta® and NEUPOGEN® are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important Safety Information

Contraindication

 Neulasta® or NEUPOGEN® are contraindicated in patients with a history of serious allergic reactions to human granulocyte colonystimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta®and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment

 Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Allergies to Acrylics

- On-body Injector for Neulasta® uses acrylic adhesives
- Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients with Sickle Cell Disorders

 In patients with sickle cell trait or disease, sickle cell crisis, in some cases fatal, can occur in patients receiving Neulasta® and NEUPOGEN®. Discontinue if sickle cell crisis occurs.

Glomerulonephritis

- Has occurred in patients receiving NEUPOGEN® and Neulasta®
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose reduction or discontinuation of NEUPOGEN® and Neulasta®
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta® or NEUPOGEN®

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including NEUPOGEN® and Neulasta®
- Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Thrombocytopenia

- Thrombocytopenia has been reported in patients who received NEUPOGEN® and pegfilgrastim
- Monitor platelet counts

Leukocytosis

- White blood cell counts of ≥ 100,000/mm³ have been observed in patients who received NEUPOGEN® and Neulasta®
- Monitor CBCs during Neulasta® therapy and at least twice weekly for NEUPOGEN®
- Adjust NEUPOGEN® dosing as clinically indicated to help mitigate risk of leukocytosis
- Dosages of NEUPOGEN® that increase the absolute neutrophil count (ANC) beyond 10,000/mm³ may not result in any additional clinical benefit
- Discontinuation of NEUPOGEN® therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days

Cutaneous Vasculitis

- Moderate or severe cases of cutaneous vasculitis have been reported in patients treated with NEUPOGEN®
- Most reports involved patients with severe chronic neutropenia on long-term NEUPOGEN® therapy
- Hold NEUPOGEN® therapy in patients with cutaneous vasculitis
- NEUPOGEN® dose may be reduced when the symptoms resolve and ANC has decreased

Potential Effect on Malignant Cells

- G-CSF receptor has been found on tumor cell lines
- The possibility that NEUPOGEN® or Neulasta® acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Patients with Severe Chronic Neutropenia

- Confirm the diagnosis of SCN before initiating NEUPOGEN® therapy
- MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy
- Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with NEUPOGEN® for SCN
- Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia.
- Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia
- The effect of NEUPOGEN® on the development of abnormal cytogenetics and the effect of continued NEUPOGEN® administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings.
- If a patient with SCN develops abnormal cytogenetics or myelodysplasia, the risks and benefits of continuing NEUPOGEN® should be carefully considered

Patients with Breast and Lung Cancer

 MDS and AML have been associated with the use of NEUPOGEN® and Neulasta® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended

- Safety and efficacy of NEUPOGEN® given simultaneously with cytotoxic chemotherapy and radiation have not been established
- Do not use NEUPOGEN® 24 hours before or after cytotoxic chemotherapy
- Avoid simultaneous use of NEUPOGEN® with chemotherapy and radiation

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes have been seen in patients taking Neulasta® or NEUPOGEN®.
- Consider when interpreting bone-imaging results

Potential Device Failures

- Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
- In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
- Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

- Aortitis has been reported in patients receiving Neulasta® and NEUPOGEN®. It may occur as early as the first week after start of therapy.
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count).
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® and NEUPOGEN® if aortitis is suspected.

Most common adverse reactions in patients taking NEUPOGEN®

 Anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, peripheral edema, decreased hemoglobin, decreased appetite, oropharyngeal pain, and alopecia

Most common adverse reactions in patients taking Neulasta®

- Bone pain
- Pain in extremity

NEUPOGEN® is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.

- Prefilled Syringe: Injection: 300 mcg/0.5 mL in a single-dose prefilled syringe; Injection: 480 mcg/0.8 mL in a single-dose prefilled syringe Neulasta® is administered by subcutaneous injection.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Please see accompanying full Prescribing Information for Neulasta® and NEUPOGEN®.





Please see additional Important Safety Information on page 11.



See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



AMGEN NURSE NAVIGATORS*

A single point of contact for Amgen Assist 360TM services, designed to help your patients find the resources[†] that are most important to them

- * Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
- [†] Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Call 1-888-4ASSIST (888-427-7478)

Monday to Friday, 9:00 AM to 8:00 PM EST,
or visit www.AmgenAssist360.com

References

1. Neulasta® (pegfilgrastim) prescribing information, Amgen. 2. Neulasta® (pegfilgrastim) Onpro® kit Healthcare Provider Instructions for Use, Amgen. 3. RED BOOK Online®. Neulasta® (pegfilgrastim) injection Onpro® kit. https://www.micromedexsolutions.com/micromedex2/librarian/CS/62DD04/ND_PR/evidencexpert/ND_P/evidencexpert/DDPLICATIONSHIELDSYNC/03D81D/ND_PG/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PActionId/redbook.ShowProductSearch Results?SearchTerm=NEULASTA%200NPRO&searchType=redbookProductName&searchTermId=44479&searchContent=REDBOOK&searchFilterAD-filterAD

AMGEN

Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com







PHYSICIAN OFFICE CODING AND BILLING INFORMATION SHEET FOR NEULASTA® ONPRO®, NEULASTA®, AND NEUPOGEN®

Contact Amgen Assist 360™ for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com

Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.¹


Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.¹

Neulasta[®] Onpro[®] kit, which includes: the same Neulasta[®] as in the Prefilled Syringe with a different delivery option¹



- Must be prepared and applied by a healthcare provider on the same day as chemotherapy¹
- The prefilled syringe co-packaged in the Neulasta® Onpro® kit must only be used with the On-body Injector for Neulasta®
- Designed to deliver a full dose of Neulasta® approximately 27 hours after its activation¹
 - As per the label, a healthcare provider may initiate administration with the On-body Injector for Neulasta® (also referred to as the "On-body Injector") on the same day as the administration of cytotoxic chemotherapy, and the On-body Injector is designed to deliver pegfilgrastim approximately 27 hours after application¹

Apply today, deliver* Neulasta® tomorrow¹



^{*} The On-body Injector for Neulasta® is designed to deliver Neulasta® approximately 27 hours after activation.

Important Safety Information

Contraindication

 Neulasta® or NEUPOGEN® are contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Please see additional Important Safety Information on pages 10-11.



Neulasta® delivered via the On-body Injector vs Neulasta® delivered via the manual use Neulasta® Prefilled Syringe

SELECT ATTRIBUTES	SAME	DIFFERENT
Active Ingredient ¹	✓	
Indication ¹	✓	
Route of Administration ¹	✓	
Deliverable Dose ¹	✓	
WAC ^{3,4}	✓	
J-code ^{5,*}	✓	
How Delivered and CPT Code ^{1,6,*}		✓
NDC Number ^{1,*}		✓

^{*} See next page for coding and billing information sheet for Neulasta®. NDC = National Drug Code; WAC = wholesale acquisition cost.

On-body Injector for Neulasta®

A missed dose could occur due to an On-body Injector for Neulasta® failure or leakage. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use, as soon as possible after detection.

The On-body Injector is backed by 24/7 telephone support and a full return policy.

Call **1-844-MYNEULASTA** at any time for assistance or answers to product-related questions.

Important Safety Information

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Please see additional Important Safety Information on pages 10-11.

Physician Office – Billing Information Sheet for the Neulasta® Onpro® kit

Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Onpro® kit	J2506, injection, pegfilgrastim,	Neulasta® is supplied as a 6 mg deliverable dose.¹
	excludes biosimilar, 0.5 mg	Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
		55513-0192-01 is the NDC number (in the 11-digit format) for Neulasta® Onpro® kit.¹
		Healthcare providers should ensure Service Units (Box 24G) are appropriately billed.
Administration of the On-body Injector	96377, application of on-body injector (includes cannula insertion) for timed	Healthcare providers can initiate administration with the On-body Injector on the same day as the administration of chemotherapy. 1,*
	subcutaneous injection	See payer guidelines for specific coding requirements.
Office visit	Relevant Evaluation and Management (E&M) code ^{†,‡}	See payer guidelines.
Diagnosis/ Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}As long as Neulasta® is not delivered between 14 days before and 24 hours after administration of cytotoxic chemotherapy.

CPT = Current Procedural Terminology; HCPCS = Healthcare Common Procedure Coding System; ICD-10-CM = International Classification of Diseases, Tenth Revision, Clinical Modification.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



[†] Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

[‡] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when modifier 25 is billed.

The CMS 1500 for Physician Office — Neulasta® Onpro® kit

Sample CMS 1500 Form — Physician Office Administration

IEALTH INSURAN	CE CLAIM FO	ORM			
PPROVED BY NATIONAL UNIFO	RM CLAIM COMMITTEE	(NUCC) 02/12			
PICA					PICA TI
MEDICARE MEDICAID	TRICARE	CHAMPV		1a. INSURED'S I.D. NUMBER	(For Program in Item 1)
(Medicare#) (Medicaid#)	(ID#/DoD#)	(Member II	O#) [(ID#) [(ID#) [(ID#)		
PATIENT'S NAME (Last Name,	First Name, Middle Initial)		3. PATIENT'S BIRTH DATE SEX	4. INSURED'S NAME (Last Na	
Doe, John D			XX XX XX M	Doe, John	
PATIENT'S ADDRESS (No., Stre			6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No.	, Street)
5555 Any St	reet		Self Spouse Child Other		
ITY		STATE	8. RESERVED FOR NUCC USE	CITY	STATE
Anytown		XX			
P CODE	TELEPHONE (Include Are	ea Code)		ZIP CODE	TELEPHONE (Include Area Code)
01010	(xxx) xxx-	XXXX			
OTHER INSURED'S NAME (Las	t Name, First Name, Midd	le Initial)	PROCEDURE CODE (BOX 240	o)	
OTHER INSURED'S POLICY OF	R GROUP NUMBER		Related administration proced		
			Use CPT® code representing proc	edure performed, sucl	n as
RESERVED FOR NUCC USE			96377, application of on-body in	jector (includes cannu	TELEPHONE (Include Area Code) () n as la insertion) for timed
			subcutaneous injection		
RESERVED FOR NUCC USE			Note: Healthcare providers can in	uitiate administration v	with the On-hady-Injector on
LESENTED I ON NOOD DOE			the same day as the administratio		with the On-body Injector on
NOUBANCE DI ANIMANE OD E	POCRAM NAME				vith the On-body Injector on hefore and 24 hours after
INSURANCE PLAN NAME OR F	NOGRAM NAME		*As long as Neulasta® is not deliv		before and 24 hours after
			administration of cytotoxic chem		
PATIENT'S OR AUTHORIZED	PERSON'S SIGNATURE	I authorize the i	R SIGNING FINE FORM. release of any medical or other information necessary to myself or to the party who accepts assignment		ED PENSON'S SIGNATIONE LAURIDIZE to the undersigned physician or supplier for
SIGNED			DATE	SIGNED	
	INJURY or PREGNANC	Y (LMP) 15 (OTHER DATE		TO WORK IN CURRENT OCCUPATION
DATE OF CURRENT ILLNESS MM DD YY XX XX XX QU		QUA	. MM . DD . VV	FROM DD	TO WORK IN CURRENT OCCUPATION YY MM DD YY TO
NAME OF REFERRING PROV		DE 17a		18. HOSPITALIZATION DATES	
			NPI	FROM DD	SERVICE UNITS (BOX 24G)
ADDITIONAL CLAIM DIA	CNOCIC CODE			THOM T	Report units of service for
ADDITIONAL CLAIM I					Neulasta® in accordance
Ente	r appropriate ICD)-10-CM d	liagnosis code(s) corresponding to p	oatient's diagnosis.	with the code descriptor
	wable diagnosis c	odes may			(i.e., 12 service units = 6 mg).
XXX.X	GNOSIS CODE	POINTER	R (BOX 24E)		
					Neulasta® dose is 6 mg,
			relating to each CPT/HCPCS code		per label.
. A. DATE(S) OF SERVICE From To			DURES, SERVICES, OR SUPPLIES in Unusual Circumstances) DIAC NOSIS	F. G. DAYS	H. J. EPSOT BENDERING
From IC M DD YY MM DE				\$ CHARGES UNITS	H. J. PSDI D. RENDERING PROVIDER ID. #
x xx xx xx x	x xx 11	J250	6 A	xxx xx 12	INPI
x xx xx xx x	1 11	9637	LCODE (BOX 24D)		H. C. RENDERING PROVIDER ID. #
AA A		1007	J2506, injection, pegfilgra	stim, excludes biosimil	ar. 0.5 mg.
	1 1 1	1			,
- 1 1 T			Note: If applicable, disca		
1 1			on a congrate line with I	2506 and the JW mod	itier.
	ov ov v		On a separate line with 32		
SERVICE DATE (B	OX 24A)		on a separate line with 32		
SERVICE DATE (B Report date of servi			on a separate line with 32		
	ce. For		on a separate line with 32		
Report date of servi example, the date v	ce. For when On-body		on a separate mile with 12		
Report date of servi example, the date v Injector from the Ne	ce. For when On-body eulasta®		On a separate line with 12		
Report date of servi example, the date v Injector from the Ne Onpro® kit was app	ce. For /hen On-body eulasta® lied.	6. PATIENT'S A			NPI
Report date of servi example, the date v Injector from the Ne	ce. For when On-body eulasta® lied.	6. PATIENT'S A	CCOUNT NO. 27. ACCEPT ASSIGNMENT?	28. TOTAL CHARGE	NPI NPI
Report date of servi example, the date v Injector from the Ne Onpro® kit was app	ce. For when On-body eulasta® lied.		CCOUNT NO. 27. ACCEPT ASSIGNMENT? [For govi. claims, see back] YES NO	28. TOTAL CHARGE \$	NPI NPI 19. AMOUNT PAID 30. Rsvd for NUCC Use
Report date of servi example, the date v Injector from the Ne Onpro® kit was app	ce. For when On-body ulasta® lied. SSN EIN OR SUPPLIER EDENTIALS When the reverse		CCOUNT NO. 27. ACCEPT ASSIGNMENT?	28. TOTAL CHARGE	NPI NPI 19. AMOUNT PAID 30. Rsvd for NUCC Use
Report date of servi example, the date v Injector from the Ne Onpro® kit was app FEDERAL TAX L.D. NUMBER SIGNATURE OF PHYSICIAN O INCLUDING DEGREES OR OF (I certify that the statements on	ce. For when On-body eulasta® lied. SSN EIN 26 PR SUPPLIER 32 BEDENTIALS the reverse part thereof.)	2. SERVICE FA	CCOUNT NO. 27. ACCEPT ASSIGNMENT? The control of the country of	28. TOTAL CHARGE \$ 33. BILLING PROVIDER INFO	NPI NPI NPI 30. Rsvd for NUCC Use \$ & PH # ()
Report date of servi example, the date v Injector from the Ne Onpro® kit was app. FEDERAL TAX LID. NUMBER SIGNATURE OF PHYSICIAN O INCLUDING DEGREES OR OF CICETIVE HE STATEMENTS ON	ce. For when On-body ulasta® lied. SSN EIN OR SUPPLIER EDENTIALS When the reverse	2. SERVICE FA	CCOUNT NO. 27. ACCEPT ASSIGNMENT? [For govi. claims, see back] YES NO	28. TOTAL CHARGE 2 \$ 33. BILLING PROVIDER INFO	NPI NPI 19. AMOUNT PAID 30. Rsvd for NUCC Use

Physician Office – Billing Information Sheet for the Neulasta® Prefilled Syringe

Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
Neulasta® Prefilled	J2506, injection, pegfilgrastim,	Neulasta® is supplied as a 6 mg deliverable dose.1
Syringe for Manual Injection	excludes biosimilar, 0.5 mg	Effective Jan 1, 2022, the HCPCS has changed from J2505 to J2506, injection, pegfilgrastim, excludes biosimilar, 0.5 mg.
		55513-0190-01 is the NDC number (in the 11-digit format) for the Neulasta® prefilled syringe for manual injection.¹
		Healthcare providers should ensure Service Units (Box 24G) are appropriately billed.
Administration of Neulasta® Prefilled Syringe for Manual Injection	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Office visit	Relevant Evaluation and Management (E&M) code*,†	See payer guidelines.
Diagnosis/Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

The information provided in this Coding and Billing Information document is of a general nature and for informational purposes only and is not intended to be a comprehensive list nor instructive. Coding and coverage policies change periodically and often without warning. The responsibility to determine coverage and reimbursement parameters, and appropriate coding for a particular patient and/or procedure, is always the responsibility of the provider or physician. The information provided in this section should in no way be considered a guarantee of coverage or reimbursement for any product or service.

Important Safety Information

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta® and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360[™] for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



[†] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when modifier 25 is billed.

The CMS 1500 for Physician Office — Neulasta® Prefilled Syringe

Sample CMS 1500 Form — Physician Office Administration

							ä
HEALTH INSURAI	NCE CLAIM FOR	RM					CARRIER
APPROVED BY NATIONAL UNIF	ORM CLAIM COMMITTEE (NU	ICC) 02/12					ა
PICA 1. MEDICARE MEDICAID) TRICARE	CHAMPV	/A GROUP FECA OTHER	1a. INSURED'S I.D. NUMBE	3	(For Program in Item 1)	┦┼
(Medicare#) (Medicaid#	(ID#/DoD#)	(Member li	ID#) HEALTH PLAN BLK LUNG (ID#)				_ ^
2. PATIENT'S NAME (Last Name Doe, John D			3. PATIENT'S BIRTH DATE SEX MM DD YY XX XX XX M F	4. INSURED'S NAME (Last N		liddle Initial)	
5. PATIENT'S ADDRESS (No., S	treet)		6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (N			\exists
5555 Any St	reet	STATE	Self Spouse Child Other 8. RESERVED FOR NUCC USE	CITY		STATE	ا ٰ۔
Anytown		XX				5,,,,,	Ē
ZIP CODE 01010	TELEPHONE (Include Area (ZIP CODE	TELEPHONE ((Include Area Code)	RMA
9. OTHER INSURED'S NAME (La	\ /		10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GR	DUP OR FECA NUM	/ //BER	
a. OTHER INSURED'S POLICY O	OR GROUP NUMBER		a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIF	TH	SEX	
			YES NO	MM DD	M[F	NSU
b. RESERVED FOR NUCC USE			b. AUTO ACCIDENT? PLACE (State) YES NO	b. OTHER CLAIM ID (Design	ated by NUCC)		- N
c. RESERVED FOR NUCC USE			c. OTHER ACCIDENT?	i c. INSURANCE PLAN NAME	OR PROGRAM NA	ME	PATIENT AND INSURED INFORMATION
J. INSURANCE PLAN NAME OR	PROGRAM NAME		PROCEDURE CODE (BOX 24D				A THE
3. INSOTIANCE I EAN NAME ON	THOUTAWINAME		Use CPT® code representing proce				1
2. PATIENT'S OR AUTHORIZED		uthorize the	subcutaneous or intramuscular	or diagnostic injecti	on (specity su	ibstance or drug);	
to process this claim. I also req below.	uest payment of government be	nefits either	ri <u></u>				
SIGNED		1	DATE	SIGNED			+
14. DATE OF CURRENT ILLNES MM DD YY XX XX XX QI	S, INJURY, or PREGNANCY (I UAL.	_MP) 15. QU	OTHER DATE MM DD YY	16. DATES PATIENT UNABL	TO		
17. NAME OF REFERRING PRO	VIDER OR OTHER SOURCE	17a	a.	18. HOSPITALIZATION DATE		URRENT SERVICES MM DD YY	
; 19. ADDITIC NAL CLAIM INFORM	MATION (Designated by NU(IOSIS CODES (BOX 21)	OUTSIDE LAB?	TO \$ CH.	ARGES	\dashv
21. DIAGNO SIS OR NATURE OF			opropriate ICD-10-CM diagnosis corresponding to patient's diagnosis	SERVICE L	INITS (BOX	24G)	41
A XXX.X	R I		ple diagnosis codes may vary by paye			or Neulasta® in	
E. L	F		IOSIS CODE POINTER (BOX 24E		with the cod vice units = 6		
I. L. DATE(S) OF SERVIC	E B C		diagnosis, from Box 21, relating to PT/HCPCS code listed in Box 24D.		ose is 6 mg, _l	per label.	- <u>'</u>
	TO PLACE OF SERVICE EMG	CPT/HCP		\$ CHARGES OF	R Family ID. FS Plan QUAL	RENDERING PROVIDER ID. #	ATION TO THE
xx xx xx :	xx xx 11	J25	06 A	xxx xx 12	NPI		OBM
					-		Į.
xx xx xx	xx xx 11	963	The contract of the contract o	n oveludos biosimila	or 0.5 mg		PLIER INFORMATION
			J2506, injection, pegfilgrastir Note: If applicable, discarded				SUPP
SERVICE DATE (I	BOX 24A)		on a separate line with J2506				- წ
Report date of serv	vice. For example, th	e L					PHYSICIAN
date when Neulast	:a® prefilled syringe on was administered.				NPI		
				Loc TOTAL OLUMBIA	NPI NPI	00 Bu 11 1915	
25. FEDERAL TAX I.D. NUMBER	SSN EIN 26. P	AΠENT'S A	ACCOUNT NO. 27. ACCEPT ASSIGNMENT? (For govt. claims, see back) YES NO	28. TOTAL CHARGE	29. AMOUNT PAID	30. Rsvd for NUCC U	se
31. SIGNATURE OF PHYSICIAN INCLUDING DEGREES OR C	OR SUPPLIER 32. S	ERVICE FA	ACILITY LOCATION INFORMATION	33. BILLING PROVIDER INF)	\parallel
(I certify that the statements o apply to this bill and are made	n the reverse						
SIGNED	DATE a.	NI	DI EASE DRINT OR TYPE	a.	b.	197 FORM 1500 (02-1	12)
IUCC Instruction Manual	avallable at: www.nucc	.org	PLEASE PRINT OR TYPE	APPROVEL	OIVID-0938-11	197 FOUNT 1900 (02-1	14)

This sample form is intended as a reference for coding and billing for product and associated services. It is not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Physicians and staff may deem other codes or policies more appropriate. Providers should select the coding options that most accurately reflect their internal system guidelines, payer requirements, practice patterns, and the services rendered. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

Neuronal Providers

Neuronal Provide

Physician Office – Billing Information Sheet for NEUPOGEN®

NEUPOGEN® (filgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.⁸

Item	Coding Information (HCPCS ⁵ /CPT ⁶ /ICD-10-CM)	Notes
NEUPOGEN®	J1442, injection, filgrastim (G-CSF), 1 mcg	The NDC numbers for NEUPOGEN®, in the 11-digit format, are as follows:8 - 300-mcg vial: 55513-0530-10 - 300-mcg prefilled syringe: 55513-0924-10 - 480-mcg vial: 55513-0546-10 - 480-mcg prefilled syringe: 55513-0209-10
Administration	96372, therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	
Office visit	Relevant Evaluation and Management (E&M) code*,†	See payer guidelines
Diagnosis/ Condition	Appropriate ICD-10-CM diagnosis code(s) for patient condition.	Allowable diagnosis codes may vary by payer.

^{*}Bill relevant E&M code only if a separately identifiable E&M service is performed. Document accordingly.

Important Safety Information

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment
- Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Please see additional Important Safety Information on pages 10-11.

Contact Amgen Assist 360™ for reimbursement and access resources at 1-888-4ASSIST or www.AmgenAssist360.com



[†] Some payers, including Medicare, will not allow a Level 1 office visit to be billed with an injection/infusion code for the same date of service, and only allow for other levels (if appropriate) when Modifier 25 is billed.

The CMS 1500 for Physician Office — NEUPOGEN®

Sample CMS 1500 Form — Physician Office Administration

] 宗国 公立記] 公元] [2] [IEALTH INSURANCE CLAIM FORM		
PPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12		
PICA		PICA T
. MEDICARE MEDICAID TRICARE CHAMPV . (Medicare#) (Medicaid#) (ID#/DoD#) (Member III	— HEALTH PLAN — BLK LUNG —	1a. INSURED'S I.D. NUMBER (For Program in Item 1)
. PATIENT'S NAME (Last Name, First Name, Middle Initial)		4. INSURED'S NAME (Last Name, First Name, Middle Initial)
Doe, John D	3. PATIENT'S BIRTH DATE SEX MM DD YY XX XX XX M F	Doe, John D
. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)
5555 Any Street	Self Spouse Child Other	
Anytown XX	8. RESERVED FOR NUCC USE	ZIP CODE TELEPHONE (Indude Area Code) () 11. INSURED'S POLICY GROUP OR FECA NUMBER a. INSURED'S DATE OF BIRTH MM DD YY M
IP CODE TELEPHONE (Include Area Code)		ZIP CODE TELEPHONE (Include Area Code)
01010 (xxx) xxx-xxxx		
OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NUMBER
. OTHER INSURED'S POLICY OR GROUP NUMBER	a. EMPLOYMENT? (Current or Previous)	a. INSURED'S DATE OF BIRTH SEX
. RESERVED FOR NUCC USE	YES NO	ML FL
. HESERVED FOR NUCC USE	b. AUTO ACCIDENT? PLACE (State)	b. OTHER CLAIM ID (Designated by NUCC)
DECEDVED FOR NILICO LICE	YES NO NO	- NICHDANGE DI AN NAME OD DDGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
J-CODE (BOX 24D)	c. OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR PROGRAM NAME
		d, IS THERE ANOTHER HEALTH BENEFIT PLAN?
J1442, injection, filgrastim (G-CSF), 1 mcg.	10d. CLAIM CODES (Designated by NUCC)	
Note: If applicable, discarded product	a & SIGNING THIS FORM.	YES NO If yes, complete items 9, 9a, and 9d. 13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize
snoula de reportea on a separate line with 📙	release of any medical or other information necessary to myself or to the party who accepts assignment	payment of medical benefits to the undersigned physician or supplier for
J1442 and the JW modifier. ⁷	to mysen or to the party who accepts assignment	services described below.
SIGNED	DIAGNO	OSIS CODE (BOX 21)
4. D TE O CURRENT ILLNESS, INJURY, or PREGNANCY (LMP) 15.	OTHER DATE	nt appropriate ICD-10-CM diagnosis
QU.	MM DD DOCUME	corresponding to patient's diagnosis.
7. N ME C REFERRING PROVIDER OR OTHER SOURCE 17a		SERVICES
17t	o. INPI	le diagnosis codes may vary by payer.
9. A DITIC NAL CLAIM INFORMATION (Designated by NUCC)		OSIS CODE (BOX 24E)
		liagnosis, from Box 21, relating to
1. D AGNOSIS OR NATURE OF ILLNESS OR INJURY Relate A-L to serv	ice line below (24E) ICD Ind. each CPT	T/HCPCS code listed in Box 24D.
а. L <mark>XXX . X</mark> в. L с. L	D. L	as abree Authoritation whites
E. L F. L G. L	——— н. 📖	23. PRIOR AUTHORIZATION NUMBER
. J. K. L	DURES, SERVICES, OR SUPPLIES E.	
From To PURCOT (Expla	in Unusual Circumstances) DIACNOSIS	F. G. H. I. J. DAYS EFSUT ID. RENDERING \$ CHARGES WITTS Plant \$ CHARGES WITTS Plant
MM DD YY MM DD YY SERVICE EMG CPT/H	CS MODIFIER POINTER	\$ CHARGES OR LANTS Plan SERVICE UNITS (BOX 2
xx xx xx xx xx 11 J144	42 A	xxx xx xxx Report unit of service. 1 u
		for J1442 corresponds to
x x x x x x x x x 11 963	72 A	xxx xx xxx 1 1 mcg of NEUPOGEN®; for
		example, 300 units for the
1 1 1 <u>1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </u>		300 mcg dose or 480 uni
PROCEDURE CODE (B	OX 24D)	for the 480 mcg dose.
Document product admir		
appropriate CPT code. Us		NPI NPI
	ch as 96372, therapeutic,	NPI NPI
prophylactic, or diagnosti		
substance or drug); subcu	utaneous or intramuscular.	NPI
5. FEDERAL TAX I.D. NUMBER SSIN EIN 26. PATIENT S A	(For govt, claims, see back)	28. TOTAL CHARGE 29. AMOUNT PAID 30. Rsvd for NUCC Use
	YES NO	\$
A CLOSUS TUBE OF BURGOOM OF STREET	CILITY LOCATION INFORMATION	33. BILLING PROVIDER INFO & PH # ()
11. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)		
INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse	b.	a. b.



Special Instructions for the On-body Injector (OBI) for Neulasta®

A healthcare provider must fill the on-body injector (OBI) with Neulasta® using the co-packaged prefilled syringe and then apply the OBI to the patient's skin (abdomen or back of arm). The back of the arm may only be used if there is a caregiver available to monitor the status of the OBI. Approximately 27 hours after the OBI is applied to the patient's skin, Neulasta® will be delivered over approximately 45 minutes. A healthcare provider may initiate administration with the OBI on the same day as the administration of cytotoxic chemotherapy, as long as the OBI delivers Neulasta® no less than 24 hours after the administration of cytotoxic chemotherapy.

The prefilled syringe co-packaged in the Neulasta® Onpro® kit contains additional solution to compensate for liquid loss during delivery through the OBI. If this syringe is used for manual subcutaneous injection, the patient will receive an overdose. If the prefilled syringe for manual use is used with the OBI, the patient may receive less than the recommended dose.

Do not use the OBI to deliver any other drug product except the Neulasta® prefilled syringe co-packaged with the OBI. Use of the OBI has not been studied in pediatric patients.

The OBI should be applied to intact, non-irritated skin on the arm or abdomen.

A missed dose could occur due to an OBI failure or leakage. Instruct patients using the OBI to notify their healthcare professional immediately in order to determine the need for a replacement dose of pegfilgrastim if they suspect that the device may not have performed as intended. If the patient misses a dose, a new dose should be administered by single prefilled syringe for manual use as soon as possible after detection.

Review the Patient Information and Patient Instructions for Use with the patient and provide the instructions to the patient. Refer to the Healthcare Provider Instructions for Use for the OBI for full administration information.

For any OBI problems, call Amgen at 1-800-772-6436 or 1-844-MYNEULASTA (1-844-696-3852).

Indication and Important Safety Information for Neulasta® (pegfilgrastim) and NEUPOGEN® (filgrastim)

Indication

Neulasta® and NEUPOGEN® are indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Neulasta® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Important Safety Information

Contraindication

 Neulasta® or NEUPOGEN® are contraindicated in patients with a history of serious allergic reactions to human granulocyte colonystimulating factors (G-CSFs), such as pegfilgrastim or filgrastim

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of Neulasta® and NEUPOGEN®
- Evaluate for an enlarged or ruptured spleen in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

- ARDS has occurred in patients receiving Neulasta®and NEUPOGEN®
- Evaluate patients who develop a fever and lung infiltrates or respiratory distress after receiving Neulasta® or NEUPOGEN®
- Discontinue Neulasta® or NEUPOGEN® in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis can occur in patients receiving Neulasta® and NEUPOGEN®
- Provide symptomatic treatment for allergic reactions
- Majority of events occurred upon initial exposure and can recur within days after discontinuation of initial anti-allergic treatment

 Permanently discontinue Neulasta® or NEUPOGEN® in patients with serious allergic reactions

Allergies to Acrylics

- On-body Injector for Neulasta® uses acrylic adhesives
- Patients who are allergic to acrylic adhesives may have a significant reaction

Use in Patients with Sickle Cell Disorders

 In patients with sickle cell trait or disease, sickle cell crisis, in some cases fatal, can occur in patients receiving Neulasta® and NEUPOGEN®. Discontinue if sickle cell crisis occurs.

Glomerulonephritis

- Has occurred in patients receiving NEUPOGEN® and Neulasta®
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose reduction or discontinuation of NEUPOGEN® and Neulasta®
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Neulasta® or NEUPOGEN®

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including NEUPOGEN® and Neulasta®
- Characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency, severity, and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include intensive care

Please see additional Important Safety Information on page 11.

Thrombocytopenia

- Thrombocytopenia has been reported in patients who received NEUPOGEN® and pegfilgrastim
- Monitor platelet counts

Leukocytosis

- White blood cell counts of ≥ 100,000/mm³ have been observed in patients who received NEUPOGEN® and Neulasta®
- Monitor CBCs during Neulasta® therapy and at least twice weekly for NEUPOGEN®
- Adjust NEUPOGEN® dosing as clinically indicated to help mitigate risk of leukocytosis
- Dosages of NEUPOGEN® that increase the absolute neutrophil count (ANC) beyond 10,000/mm³ may not result in any additional clinical benefit
- Discontinuation of NEUPOGEN® therapy usually resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, with a return to pretreatment levels in 1 to 7 days

Cutaneous Vasculitis

- Moderate or severe cases of cutaneous vasculitis have been reported in patients treated with NEUPOGEN®
- Most reports involved patients with severe chronic neutropenia on long-term NEUPOGEN® therapy
- Hold NEUPOGEN® therapy in patients with cutaneous vasculitis
- NEUPOGEN® dose may be reduced when the symptoms resolve and ANC has decreased

Potential Effect on Malignant Cells

- G-CSF receptor has been found on tumor cell lines
- The possibility that NEUPOGEN® or Neulasta® acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Patients with Severe Chronic Neutropenia

- Confirm the diagnosis of SCN before initiating NEUPOGEN® therapy
- MDS and AML have been reported to occur in the natural history of congenital neutropenia without cytokine therapy
- Cytogenetic abnormalities, transformation to MDS, and AML have also been observed in patients treated with NEUPOGEN® for SCN
- Based on available data including a postmarketing surveillance study, the risk of developing MDS and AML appears to be confined to the subset of patients with congenital neutropenia.
- Abnormal cytogenetics and MDS have been associated with the eventual development of myeloid leukemia
- The effect of NEUPOGEN® on the development of abnormal cytogenetics and the effect of continued NEUPOGEN® administration in patients with abnormal cytogenetics or MDS are unknown. Monitor patients for signs and symptoms of MDS/AML in these settings.
- If a patient with SCN develops abnormal cytogenetics or myelodysplasia, the risks and benefits of continuing NEUPOGEN® should be carefully considered

Patients with Breast and Lung Cancer

 MDS and AML have been associated with the use of NEUPOGEN® and Neulasta® in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Simultaneous Use with Chemotherapy and Radiation Therapy Not Recommended

- Safety and efficacy of NEUPOGEN® given simultaneously with cytotoxic chemotherapy and radiation have not been established
- Do not use NEUPOGEN® 24 hours before or after cytotoxic chemotherapy
- Avoid simultaneous use of NEUPOGEN® with chemotherapy and radiation

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow has been associated with transient positive bone-imaging changes have been seen in patients taking Neulasta® or NEUPOGEN®.
- Consider when interpreting bone-imaging results

Potential Device Failures

- Missed or partial doses have been reported in patients receiving pegfilgrastim via the on-body injector (OBI) due to the device not performing as intended
- In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered
- Instruct patients to notify their healthcare professional immediately in order to determine the need for a replacement dose if they suspect that the device may not have performed as intended

Aortitis

- Aortitis has been reported in patients receiving Neulasta® and NEUPOGEN®. It may occur as early as the first week after start of therapy.
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count).
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Neulasta® and NEUPOGEN® if aortitis is suspected.

Most common adverse reactions in patients taking NEUPOGEN®

 Anemia, constipation, diarrhea, oral pain, vomiting, asthenia, malaise, peripheral edema, decreased hemoglobin, decreased appetite, oropharyngeal pain, and alopecia

Most common adverse reactions in patients taking Neulasta®

- Bone pain
- Pain in extremity
- NEUPOGEN® is administered by subcutaneous injection, short intravenous infusion (15 to 30 minutes), or continuous intravenous infusion.
- Prefilled Syringe: Injection: 300 mcg/0.5 mL in a single-dose prefilled syringe; Injection: 480 mcg/0.8 mL in a single-dose prefilled syringe Neulasta® is administered by subcutaneous injection.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.
- Injection: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector (OBI) for Neulasta® (Neulasta® Onpro® kit).

Please see full <u>Prescribing Information</u> for Neulasta® and full Prescribing Information for NEUPOGEN®.







See How We Can Help Your Patients

Offering the tools, information, and support for Amgen products that make a difference for you and your patients



BENEFIT VERIFICATION

Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product



AMGEN REIMBURSEMENT SPECIALISTS

Connect with an Amgen Reimbursement Counselor, or schedule a visit with a Field Reimbursement Specialist



AMGEN NURSE NAVIGATORS*

A single point of contact for Amgen Assist 360™ services, designed to help your patients find the resources[†] that are most important to them

- * Amgen Nurse Navigators are only available to patients that are prescribed certain products. Nurse Navigators are there to support, not replace, your treatment plan and do not provide medical advice or case management services. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.
- [†] Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

Call 1-888-4ASSIST (888-427-7478)

Monday to Friday, 9:00 AM to 8:00 PM EST,
or visit www.AmgenAssist360.com

References

1. Neulasta® (pegfilgrastim) prescribing information, Amgen. 2. Neulasta® (pegfilgrastim) Onpro® kit Healthcare Provider Instructions for Use, Amgen. 3. RED BOOK Online®. Neulasta® (pegfilgrastim) injection Onpro® kit. https://www.micromedexsolutions.com/micromedex2/librarian/C5/62DD04/ND_PR/evidencexpert/ND_P/evidencexpert/DDPLICATIONSHIELDSYNC/03D81D/ND_PG/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PActionId/redbook.ShowProductSearch Results?SearchTerm=NEULASTA%20ONPRO&searchType=redbookProductName&searchTermId=44479&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilter Repackager=filterExcludeRepackager&searchPattern=%5Eneulasta. Accessed September 23, 2021. 4. RED BOOK Online®. Neulasta® (pegfilgrastim) injection. https://www.micromedexsolutions.com/micromedex2/librarian/C5/62DD04/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/03D81D/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_AppProduct/evidencexpert/ND_AppProduct/evidencexpert/ND_Afficedbook.ShowProductSearchRemsIts?SearchTerm=NEULASTA&searchType=redbookProductName&searchTermId=30621&searchContent=REDBOOK&searchFilterAD=filterADActive&searchFilterRepackager=filterExcludeRepackager&searchPattern=%5Eneulasta. Accessed September 23, 2021. 5. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Decisions. https://www.cms.gov/files/document/2021-hcpcs-application-summary-bi-annual-1-2021-non-drug-and-non-biological-items-and-services.pdf. Accessed November 1, 2021. 6. American Medical Association. Current Procedural Terminology (CPT®) 2021 Professional Edition. American Medical Association. 2020. 7. Centers for Medicare & Medicaid Services. Medicare Program JW Modifier-https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/JW-Modifier-FAQs.pdf. Accessed October 8, 2021. 8. NEUPPGEN® (filterstim) prescribing information, Amgen.



Amgen One Amgen Center Drive Thousand Oaks, CA 91320-1799 www.amgen.com